Eribulin
- Generic Name
- Eribulin
- Brand Names
- Halaven, Eribulin Baxter, Mevlyq
- Drug Type
- Small Molecule
- Chemical Formula
- C40H59NO11
- CAS Number
- 253128-41-5
- Unique Ingredient Identifier
- LR24G6354G
- Background
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid ...
- Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
- Associated Conditions
- Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
- Associated Therapies
- -
A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 90
- Registration Number
- NCT03051659
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
- Conditions
- Interventions
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- Eisai GmbH
- Target Recruit Count
- 353
- Registration Number
- NCT03027245
- Locations
- 🇩🇪
Eisai Trial Site 2, Stuttgart, Germany
🇩🇪Eisai Trial Site 3, Munchen, Germany
🇩🇪EISAI Trial Site 1, Dresden, Germany
To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 14
- Registration Number
- NCT03002493
- Locations
- 🇳🇱
Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱University Medical Center Utrecht, Utrecht, Netherlands
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
- Conditions
- Interventions
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 178
- Registration Number
- NCT02915744
- Locations
- 🇺🇸
Investigator Site - Plantation, Plantation, Florida, United States
🇺🇸Investigator Site - Boston, Boston, Massachusetts, United States
🇺🇸Investigator Site - Columbus, Columbus, Ohio, United States
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
- Conditions
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Oncologia Medica dell'Ospedale Fatebenefratelli
- Target Recruit Count
- 200
- Registration Number
- NCT02864030
- Locations
- 🇮🇹
Comprensorio sanitario di Bolzano, Bolzano, Italy
🇮🇹Istituti Ospitalieri di Cremona, Cremona, Italy
🇮🇹A.O.U. Careggi, Firenze, Italy
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 28
- Registration Number
- NCT02824575
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT02753595
PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 41
- Registration Number
- NCT02723877
- Locations
- 🇬🇧
Churchill hospital, Oxford, United Kingdom
🇪🇸Insitut Català d´Oncologia, Barcelona, Spain
🇬🇧Barts Cancer Institute, London, United Kingdom
ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 8
- Registration Number
- NCT02681523
- Locations
- 🇬🇧
Charing Cross Hopsital, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.